** Shares of drug developer vTv Therapeutics VTVT.O rise 19.2% to $17.70, their biggest one-day percentage win in more than one year
** Co says U.S. FDA has lifted clinical hold on development of cadisegliatin, an oral adjunctive therapy to insulin therapy for treatment of type 1 diabetes
** Co plans to resume its late-stage trial for the therapy after submitting protocol amendment to shorten trial from 12 to 6 months
** Up to last close, stock down 12.9% in last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.